Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines

被引：38

作者：

Westdijk, Janny ^{[1
]}

Brugmans, Debbie ^{[1
]}

Martin, Javier ^{[2
]}

van't Oever, Aart ^{[1
]}

Bakker, Wilfried A. M. ^{[1
]}

Levels, Lonneke ^{[3
]}

Kersten, Gideon ^{[1
]}

机构：

[1] Natl Inst Publ Hlth, Unit Vaccinol, NL-3720 AL Bilthoven, Netherlands

[2] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England

[3] Netherlands Vaccine Inst, NL-3720 AL Bilthoven, Netherlands

来源：

VACCINE | 2011年 / 29卷 / 18期

关键词：

Inactivated polio vaccine; Sabin; Antigenicity; Immunogenicity; IMMUNOGENICITY; STRAINS; ASSAYS; IMMUNIZATION; BIRTH; RATS;

D O I：

10.1016/j.vaccine.2011.02.085

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

GMP-batches of Sabin-IPV were characterized for their antigenic and immunogenic properties. Antigenic fingerprints of Sabin-IPV reveal that the D-antigen unit is not a fixed amount of antigen but depends on antibody and assay type. Instead of the D-antigen unit we propose standardization of IPV based on a combination of protein amount for dose and D-antigenicity for quality of the vaccine. Although Sabin-IPV type 2 is less immunogenic than regular wild type IPV type 2, the immunogenicity (virus neutralizing titers) per microgram antigen for Sabin-IPV type 2 is in the same order as for wild type serotypes 1 and 3. The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：3390 / 3397

页数：8

共 28 条

[1]

ALBRECHT P, 1984, REV INFECT DIS, V6, pS540

[2]

DERNICK R, 1981, DEV BIOLOGICALS, V47, P319

[3]

Doi Y, 2001, Dev Biol (Basel), V105, P163

[4] Poliomyelitis eradication [J].

Dowdle, WR ;

Featherstone, DA ;

Birmingham, MF ;

Hull, HF ;

Aylward, RB .

VIRUS RESEARCH, 1999, 62 (02) :185-192

[5] Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: A new surrogate method for predicting vaccine efficacy [J].

Dragunsky, EM ;

Ivanov, AP ;

Wells, VR ;

Ivshina, AV ;

Rezapkin, GV ;

Abe, S ;

Potapova, SG ;

Enterline, JC ;

Hashizume, S ;

Chumakov, KM .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (08) :1404-1412

[6]

HEUKESHOVEN J, 1981, Z NATURFORSCH C, V36, P164

[7] Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains [J].

Kersten, G ;

Hazendonk, T ;

Beuvery, C .

VACCINE, 1999, 17 (15-16) :2059-2066

[8] IMMUNOGENICITY OF TRYPSIN-TREATED TYPE-2 AND TYPE-3 POLIOVIRUS IN RATS [J].

KERSTEN, GFA ;

LANTINGA, M ;

HAZENDONK, T ;

BEUVERY, EC .

BIOLOGICALS, 1995, 23 (02) :179-183

[9]

Koch F., 1985, The Molecular Biology of Poliovirus, V1985, DOI [10.1007/978-3-7091-7000-7, DOI 10.1007/978-3-7091-7000-7]

[10] Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth [J].

Linder, N ;

Handsher, R ;

German, B ;

Sirota, L ;

Bachman, H ;

Zinger, S ;

Mendelson, E ;

Barzilai, A .

ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2000, 83 (01) :F24-F27

← 1 2 3 →